Dotmatics provides single point of access for AstraZeneca scientists
29 July 2013Tweet
AstraZeneca's Neuroscience Innovative Medicines Unit (iMed) has selected Dotmatics' cloud-based informatics platform as its research data management solution.
The Dotmatics platform provides a single point of access to all data and functions across multidisciplinary groups. The platform includes compound registration and tracking, biological screening, DMPK analysis, as well as a fully integrated chemistry and biology ELN and project management.
Dotmatics says this flexibility enables AstraZeneca scientists, collaborators and partners to instantly interact with the same data regardless of location and timezone, fulfilling the promise of real time research.
The AstraZeneca Neuroscience iMed’s strategy focuses on accessing cutting-edge science and world-class capabilities through partnership and collaboration with academia, industry and contract research organisations. The iMed manages a portfolio of drug discovery and development projects exclusively with external partners. Since it was created just over a year ago, the iMed has implemented innovative technologies that enable it to work seamlessly with external partners.
'We are excited to see the Dotmatics platform enabling and enriching the collaborative research capabilities of AstraZeneca’s Neuroscience iMed,' said Stephen Gallagher, CEO of Dotmatics.
'Today’s industry demands modern informatics solutions to accommodate the different ways in which people work, be it internally or externally, with CROs or partners. Our platform delivers this and, at the same time, eliminates the IT burden associated with global informatics infrastructure.'